Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVTENASDAQ:EWTXNASDAQ:SVRANASDAQ:TYRA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$17.45-1.2%$22.56$9.41▼$32.42$502.70M1.4187,705 shs298,877 shsEWTXEdgewise Therapeutics$17.13-2.1%$17.47$5.12▼$21.60$1.60B0.15631,001 shs964,704 shsSVRASavara$4.09-0.5%$4.67$2.56▼$5.70$565.19M0.73826,698 shs2.29 million shsTYRATyra Biosciences$16.22+3.0%$16.84$10.38▼$20.67$852.20M1.08114,339 shs107,175 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%+2.11%-15.90%-26.77%+7.38%EWTXEdgewise Therapeutics0.00%+0.12%-11.20%+2.64%+69.27%SVRASavara0.00%+0.25%-12.61%-20.74%+48.73%TYRATyra Biosciences0.00%-6.35%-12.47%-18.62%+12.09%Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate Therapeutics1.4172 of 5 stars3.50.00.00.02.12.50.6EWTXEdgewise Therapeutics1.6883 of 5 stars3.51.00.00.03.22.50.0SVRASavara2.267 of 5 stars4.51.00.00.01.51.70.6TYRATyra Biosciences2.0937 of 5 stars3.42.00.00.02.93.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics3.00Buy$47.00169.34% UpsideEWTXEdgewise Therapeutics3.00Buy$31.2082.14% UpsideSVRASavara3.00Buy$9.17124.12% UpsideTYRATyra Biosciences2.75Moderate Buy$23.5044.88% UpsideCurrent Analyst RatingsLatest TYRA, AVTE, SVRA, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2024AVTEAerovate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$41.005/21/2024SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$9.50 ➝ $11.005/16/2024SVRASavaraEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $7.005/14/2024AVTEAerovate TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$41.005/13/2024SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.005/13/2024TYRATyra BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$25.00 ➝ $28.005/10/2024TYRATyra BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$28.005/10/2024TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.005/6/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.004/22/2024EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$28.00 ➝ $32.004/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.16 per shareN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/A$5.73 per shareN/ASVRASavaraN/AN/AN/AN/A$0.88 per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$7.42 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$3.04N/AN/AN/AN/A-70.24%-61.93%8/12/2024 (Estimated)EWTXEdgewise Therapeutics-$100.16M-$1.55N/AN/AN/AN/A-29.09%-27.57%8/8/2024 (Estimated)SVRASavara-$54.70M-$0.37N/AN/AN/AN/A-51.95%-40.45%8/8/2024 (Estimated)TYRATyra Biosciences-$69.13M-$1.68N/AN/AN/AN/A-28.61%-26.97%8/8/2024 (Estimated)Latest TYRA, AVTE, SVRA, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024EWTXEdgewise Therapeutics-$0.39-$0.33+$0.06-$0.33N/AN/A5/9/2024Q1 2024SVRASavara-$0.10-$0.11-$0.01-$0.11N/AN/A5/9/2024Q1 2024TYRATyra Biosciences-$0.46-$0.35+$0.11-$0.35N/AN/A3/25/2024Q4 2023AVTEAerovate Therapeutics-$0.68-$0.74-$0.06-$0.74N/AN/A3/19/2024Q4 2023TYRATyra Biosciences-$0.48-$0.53-$0.05-$0.53N/AN/A3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A6.656.65EWTXEdgewise TherapeuticsN/A37.0837.08SVRASavara0.2214.9014.90TYRATyra BiosciencesN/A44.8344.83OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AEWTXEdgewise TherapeuticsN/ASVRASavara87.93%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%EWTXEdgewise Therapeutics24.11%SVRASavara5.13%TYRATyra Biosciences15.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics5128.81 million21.64 millionOptionableEWTXEdgewise Therapeutics9293.40 million70.88 millionOptionableSVRASavaraN/A138.19 million131.10 millionOptionableTYRATyra Biosciences4952.54 million44.45 millionOptionableTYRA, AVTE, SVRA, and EWTX HeadlinesRecent News About These CompaniesMay 30 at 11:54 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $15.94May 29, 2024 | marketbeat.comShort Interest in Tyra Biosciences, Inc. (NASDAQ:TYRA) Decreases By 40.4%May 28, 2024 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Down 4.4% May 23, 2024 | prnewswire.comTyra Biosciences to Present at Upcoming Investor ConferencesMay 17, 2024 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Down 4.6% May 16, 2024 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Up 4.7%May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: TYRA-300’s Progress and Potent FGFR3 Inhibition Signal Promising Outcomes for Tyra BioscienceMay 13, 2024 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Rating Reiterated by OppenheimerMay 11, 2024 | markets.businessinsider.comBuy Rating for Tyra Bioscience Amid Promising TYRA-300 Developments and Strong FinancialsMay 10, 2024 | marketbeat.comWedbush Reaffirms Outperform Rating for Tyra Biosciences (NASDAQ:TYRA)May 10, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Tyra Biosciences (NASDAQ:TYRA)May 10, 2024 | investorplace.comTYRA Stock Earnings: Tyra Biosciences Beats EPS for Q1 2024May 9, 2024 | prnewswire.comTyra Biosciences Reports First Quarter 2024 Financial Results and HighlightsMay 7, 2024 | prnewswire.comTyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S.March 26, 2024 | markets.businessinsider.comTyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug DevelopmentMarch 19, 2024 | msn.comTYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023March 19, 2024 | finance.yahoo.comTyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline ProgressMarch 19, 2024 | msn.comTyra Biosciences files to sell 15.37M shares of common stock for holdersMarch 19, 2024 | finance.yahoo.comTyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and HighlightsMarch 18, 2024 | insidertrades.comTyra Biosciences, Inc. (NASDAQ:TYRA) COO Daniel Bensen Sells 1,733 SharesMarch 6, 2024 | finance.yahoo.comInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 SharesNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAerovate TherapeuticsNASDAQ:AVTEAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Edgewise TherapeuticsNASDAQ:EWTXEdgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Tyra BiosciencesNASDAQ:TYRATyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.